Immuneering Corporation (IMRX) is experiencing a notable increase in its stock price, rising 14.18% to $1.95 as of 11:41 AM on November 14, following an opening price of $1.86. The stock has seen a high of $2.17 and a low of $1.85 today, with a trading volume of 1,071,701 shares, which is 19.37% of its average daily volume of 5,531,507 shares. This surge comes after the company reported its third-quarter financial results and provided business updates, including positive initial data from its Phase 2a clinical trial of IMM-1-104 in combination with chemotherapy for first-line pancreatic cancer patients. The company also announced that it has been granted FDA Orphan Drug and Fast Track designations for IMM-1-104, which could expedite its development and approval process.